3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Breast Neoplasms
14
Polycystic Ovary Syndrome
9
Neoplasms
5
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Peripheral Nervous System Diseases
2
Obesity
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Leiomyoma
2
Insulin Resistance
2
Inflammation
2
Infertility, Female
2
Glioblastoma
2
Diabetes Mellitus
2
Colorectal Neoplasms
2
Cognitive Dysfunction
2
Cardiotoxicity
2
Weight Gain
1
Vomiting
1
Venous Thromboembolism
1
Vascular Malformations
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Interventions
Cyclophosphamide
57
fludarabine phosphate
48
Tacrolimus
39
Peripheral Blood Stem Cell Transplantation
37
Busulfan
36
Mycophenolic Acid
34
Whole-Body Irradiation
31
Antilymphocyte Serum
28
Methotrexate
26
Cyclosporine
25
fludarabine
23
Melphalan
18
Filgrastim
15
Radiotherapy
14
thymoglobulin
12
ruxolitinib
12
Methylprednisolone
12
Cord Blood Stem Cell Transplantation
12
Stem Cell Transplantation
11
Sirolimus
11
Psychiatric Rehabilitation
9
Flow Cytometry
9
Etoposide
9
Specimen Handling
7
Granulocyte Colony-Stimulating Factor
7
merphos
6
Therapeutics
6
Decitabine
6
Cyclosporins
6
Azacitidine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Primary Myelofibrosis
×
Tablets
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled